Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BHV3000-406 (C4951004): A Phase 4, Randomized, Double-blind Placebo-Controlled, Efficacy and Tolerability Trial of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use

NCT05509400 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT05509400
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05509400 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BHV3000-406 (C4951004): A Phase 4, Randomized, Double-blind Placebo-Controlled, Efficacy and Tolerability Trial of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use
Lead sponsor
Pfizer
Phase
Phase 4
Overall status
Completed
Start date
October 18, 2022
Completion date
June 10, 2025
Enrollment
813 (actual)
Sites
93

Conditions

As the registry lists them; a condition with its own page is linked.

migraine